Perimetrical Findings in the double frequency perimetry (PDT) in the treatment of branch vein with Lucentis (Ranibizumab)

Trial Profile

Perimetrical Findings in the double frequency perimetry (PDT) in the treatment of branch vein with Lucentis (Ranibizumab)

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Retinal vascular occlusion
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top